预约演示
更新于：2025-04-29
Scopolamine Hydrobromide Hydrate
氢溴酸东莨菪碱
更新于：2025-04-29
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C17H28BrNO7 |
InChIKeyLACQPOBCQQPVIT-SEYKEWMNSA-N |
CAS号6533-68-2 |
关联
74
项与 氢溴酸东莨菪碱 相关的临床试验NCT06014385
A Trial to Evaluate Target Occupancy of Scopolamine at the Muscarinic M1 Receptor
ChiCTR2500097562
Prognostic impact of scopolamine hydrobromide injection in patients with hyperlactate septic shock: a prospective, multicentre, randomised, double-blind, placebo-parallel controlled clinical study
PACTR202407805328722
Effect of hyoscine N-Butyl bromide on progress of labour and pregnancy outcome; A randomized control trial
100 项与 氢溴酸东莨菪碱 相关的临床结果
登录后查看更多信息
100 项与 氢溴酸东莨菪碱 相关的转化医学
登录后查看更多信息
100 项与 氢溴酸东莨菪碱 相关的专利（医药）
登录后查看更多信息
1,186
项与 氢溴酸东莨菪碱 相关的文献（医药）2025-03-01NEUROSCIENCE LETTERS
1-Epilupinine enhances cognition and reduces inflammation in scopolamine-induced dementia model mice
Article
作者: Du, Jing ; Xu, Jiyi ; Wang, Chuanyue ; Ji, Tengfei ; Xie, Xiaomeng ; Zhang, Chenhui ; Xu, Fang
Dementia is a growing global public health concern. The search for effective anti-dementia drugs with fewer side effects, particularly in the early stages of the disease, is a key focus of current research. Natural compounds like 1-Epilupinine (ELP) may offer therapeutic potential for cognitive improvement and neuroprotection. To assess the potential of ELP in improving dementia and neuroinflammation in a scopolamine-induced dementia model in mice, a mouse model was induced using scopolamine hydrobromide, with Donepezil as the positive control. After five days of treatment, cognitive performance was assessed using the Morris water maze test. Motor function and anxiety-related behaviors were evaluated through the open field test. An inflammatory factor array was employed to measure inflammatory markers in the prefrontal cortex. The Morris water maze showed that the model group treated with scopolamine hydrobromide (1 mg/kg) had significantly fewer platform crossings and longer latency (P < 0.001) while mice treated with ELP (5 mg/kg) exhibited improved performance, with more crossings and reduced latency (P < 0.01), suggesting ELP effectively reversed cognitive deficits. In the open field test, no significant difference of total movement distance was detected in ELP-treated groups, indicating it did not impair motor function. The result of the inflammation factors array detecting showed lower levels of GM-CSF, IFN-γ, IL-2, and IL-23 significantly in the ELP (5 mg/kg) group, suggesting its potential anti-inflammatory properties for the dementia treatment. Therefore, ELP may serve as a promising treatment for early-stage dementia, offering cognitive improvement alongside anti-inflammatory neuroprotection.
2025-03-01ChemistryOpen
Synergistic Antiemetic Effects of Nerolidol on Domperidone, Hyoscine, and Ondansetron: In Vivo and in Silico Investigations on Receptor Binding Affinity
Article
作者: Bhuia, Md. Shimul ; Ghosh Situ, Sharmita ; Akber Ansari, Siddique ; Torequl Islam, Muhammad ; Chowdhury, Raihan ; Aamer Ansari, Irfan ; Ali, Arman ; Al Hasan, Sakib
Abstract:
The present study was designed to measure the potential antiemetic properties of nerolidol (NDL) via in vivo and in silico studies. To induce emesis copper sulfate pentahydrate (CuSO4.5H2O) was administered at a dose of 50 mg/kg (orally) to 2‐day‐old chicks. The test sample (NDL) was given at two doses of 50 and 100 mg/kg. b.w. orally. Additionally, aprepitant (16 mg/kg), domperidone (6 mg/kg), hyoscine (21 mg/kg), ondansetron (5 mg/kg), and diphenhydramine (10 mg/kg) were given also orally as positive controls. To observe the modulatory effects of the test sample, combination therapies with reference drugs were also administered to three different groups of animals. Molecular docking and visualization of ligand‐receptor interaction were performed against several emesis‐inducing receptors (5HT3, D2, D3, H1, and M1‐M5) using diverse computational tools. Pharmacokinetics and drug‐likeness of the selected ligands were also calculated. Findings demonstrated that NDL significantly (p <0.05) dose‐dependently lessens the mean number of retches and delays the emetic onset in the chicks. The combined drug therapy with ondansetron exposed better antiemetic activity. In addition, in silico analysis, NDL has greater binding affinity (−7.3 kcal/mol) against M2 and M3 receptors. In conclusion, NDL exerted mild antiemetic activity with synergistic properties through muscarinic receptors.
2025-01-01GUT
Combined MRI, high-resolution manometry and a randomised trial of bisacodyl versus hyoscine show the significance of an enlarged colon in constipation: the RECLAIM study
Article
作者: Atkinson, David ; Zdanaviciene, Ausra ; Hoad, Caroline Louise ; Marciani, Luca ; Gowland, Penny ; Coupland, Carol ; Dinning, Philip ; Scott, Mark ; Wilkinson-Smith, Victoria ; Sansone, Stefano ; Knowles, Charles H ; Taylor, Stuart A ; Menys, Alex ; Wiklendt, Lukasz ; Spiller, Robin C ; Corsetti, Maura
Background:
Colonic motility in constipation can be assessed non-invasively using MRI.
Objective:
To compare MRI with high-resolution colonic manometry (HRCM) for predicting treatment response.
Design:
Part 1: 44 healthy volunteers (HVs), 43 patients with irritable bowel syndrome with constipation (IBS-C) and 37 with functional constipation (FC) completed stool diaries and questionnaires and underwent oral macrogol (500–1000 mL) challenge. Whole gut transit time (WGTT), segmental colonic volumes (CV), MRI-derived Motility Index and chyme movement by ‘tagging’ were assessed using MRI and time to defecation after macrogol recorded. Left colonic HRCM was recorded before and after a 700 kcal meal. Patients then proceeded to Part 2: a randomised cross-over study of 10-days bisacodyl 10 mg daily versus hyoscine 20 mg three times per day, assessing daily pain and constipation.
Results:
Part 1: Total CVs median (range) were significantly greater in IBS-C (776 (595–1033)) and FC (802 (633–951)) vs HV (645 (467–780)), p<0.001. Patients also had longer WGTT and delayed evacuation after macrogol. IBS-C patients showed significantly reduced tagging index and less propagated pressure wave (PPW) activity during HRCM versus HV. Compared with FC, IBS-C patients were more anxious and reported more pain. Abnormally large colons predicted significantly delayed evacuation after macrogol challenge (p<0.02), impaired manometric meal response and reduced pain with bisacodyl (p<0.05).Part 2: Bisacodyl compared with hyoscine increased bowel movements but caused more pain in both groups (p<0.03).
Conclusion:
An abnormally large colon is an important feature in constipation which predicts impaired manometric response to feeding and treatment responses. HRCM shows that IBS-C patients have reduced PPW activity.
Trial registration number:
The study was preregistered on ClinicalTrials.gov, Reference:NCT03226145.
100 项与 氢溴酸东莨菪碱 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 躁郁症 | 中国 | 1981-01-01 | |
| 妊娠剧吐 | 中国 | 1981-01-01 | |
| 晕动病 | 中国 | 1981-01-01 | |
| 中毒 | 中国 | 1981-01-01 | |
| 脓毒性休克 | 中国 | 1981-01-01 | |
| 痉挛 | 中国 | 1981-01-01 | |
| 麻醉 | 日本 | 1961-12-01 | |
| 脑炎后帕金森病 | 日本 | 1961-12-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 恶心 | 申请上市 | 美国 | 2024-01-30 | |
| 呕吐 | 申请上市 | 美国 | 2024-01-30 | |
| 重度抑郁症 | 临床1期 | 美国 | 2018-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 83 | dexmedetomidine+Compazine+Total intravenous anesthesia+Fentanyl+scopolamine transdermal+sugammadex+Reglan+Propofol+Ondansetron+Aprepitant 80 mg Oral Capsule+Dexamethasone (Intervention Arm) | 鑰淵糧糧夢築願壓製築 = 窪膚醖獵顧夢鹹夢願顧 襯鑰鬱廠壓窪夢築廠餘 (膚餘繭顧壓觸衊夢醖廠, 遞網簾簾觸鏇艱衊鹽窪 ~ 廠鬱鹽衊遞齋鬱淵構衊) 更多 | - | 2024-02-14 | ||
(Control Arm) | 鑰淵糧糧夢築願壓製築 = 襯窪餘廠積廠廠夢簾淵 襯鑰鬱廠壓窪夢築廠餘 (膚餘繭顧壓觸衊夢醖廠, 膚鏇夢鬱夢網範範壓選 ~ 壓齋襯鹹鏇遞鹽夢積積) 更多 | ||||||
临床3期 | 503 | 糧製繭製願製願鹹鬱淵(鏇鑰遞構壓衊築積顧窪) = Findings showed the proportion of patients that met the primary endpoint was significantly greater in the intranasal scopolamine arm compared with the placebo arm (P <.0001). Intranasal scopolamine was also found to be significantly more effective at reducing moderate to severe nausea than placebo (P <.0001). 鑰製鬱鹽簾簾蓋蓋齋鏇 (鑰築遞餘衊鏇淵襯醖鹽 ) 更多 | 积极 | 2023-06-06 | |||
Placebo | |||||||
临床4期 | 240 | (Scopolamine Patch) | 鬱艱鹹觸鏇廠網衊鹽壓 = 憲淵艱網遞壓顧膚選網 觸觸窪壓醖鑰積糧積衊 (醖窪鏇衊遞蓋願衊醖鏇, 獵觸遞壓憲遞淵夢鏇襯 ~ 願醖製艱醖蓋願餘積餘) 更多 | - | 2022-12-28 | ||
acupressure point P6 (Acupressure Point P6) | 鬱艱鹹觸鏇廠網衊鹽壓 = 餘繭糧觸鬱鹽蓋齋網襯 觸觸窪壓醖鑰積糧積衊 (醖窪鏇衊遞蓋願衊醖鏇, 艱夢糧範簾廠願築夢願 ~ 鑰餘鹹艱窪艱網鏇襯壓) 更多 | ||||||
早期临床1期 | 90 | Placebo+Scopolamine patch (Placebo) | 餘構積鹽繭醖鑰構觸鬱(淵餘繭遞積餘襯網築遞) = 積糧鏇餘膚餘製製積壓 淵壓膚窪製鬱選鏇衊積 (網餘積築夢選網網鹹顧, 0.6) 更多 | - | 2022-08-22 | ||
Medication Therapy Management (MTM)+Scopolamine patch (Medication Therapy Management (MTM)) | 餘構積鹽繭醖鑰構觸鬱(淵餘繭遞積餘襯網築遞) = 膚壓鏇獵選窪艱餘鹽鹹 淵壓膚窪製鬱選鏇衊積 (網餘積築夢選網網鹹顧, 0.6) 更多 | ||||||
临床4期 | 14 | placebo (Control(Placebo)) | 鹽鑰顧鹹糧廠願範糧獵(顧鬱齋網鏇範糧鬱淵窪) = 鏇網衊繭窪艱糧蓋願鹹 壓淵膚築艱築憲獵製簾 (範艱夢壓獵壓窪衊窪鑰, 醖齋襯壓壓鬱餘鬱膚鑰 ~ 鹹觸顧繭鬱憲鏇積繭鹹) 更多 | - | 2019-05-20 | ||
Naltrexone+Scopolamine (Active(Scopolamine and Naltrexone)) | 鹽鑰顧鹹糧廠願範糧獵(顧鬱齋網鏇範糧鬱淵窪) = 鏇糧構構築襯餘夢築鏇 壓淵膚築艱築憲獵製簾 (範艱夢壓獵壓窪衊窪鑰, 餘繭膚艱窪顧鹹憲齋鏇 ~ 範範範構齋衊築餘蓋積) 更多 | ||||||
临床2/3期 | 63 | (PK: Scopolamine Only, Open-label) | 憲壓艱醖選襯願艱繭簾(憲製廠構膚襯憲憲選鹽) = 壓獵夢襯蓋醖構繭憲積 窪鹹艱齋鑰壓廠糧選淵 (網鏇齋衊壓衊遞積窪衊, 膚壓艱鹽淵艱餘繭觸齋 ~ 願鑰齋窪顧夢構廠餘壓) 更多 | - | 2018-01-17 | ||
Placebo+Scopolamine (Efficacy: Scopolamine and Placebo (Crossover, Double-blind)) | 鹹鑰鹹衊顧蓋襯觸鑰廠(蓋艱蓋衊衊齋繭糧製蓋) = 襯觸鬱遞築鹹艱範齋積 製齋鏇襯壓願獵選鹹網 (鹽鹽糧獵衊艱鹹艱製鏇, 105) 更多 | ||||||
临床2期 | 7 | (Scopolamine) | 膚醖鏇顧願網淵鏇獵願(顧顧衊鹽網觸齋廠窪遞) = 選鑰願觸鑰範遞願齋鑰 壓繭獵鹽齋選鏇鏇獵鹽 (鬱願衊膚艱餘艱鑰鏇糧, 10.47) 更多 | - | 2017-04-18 | ||
(Placebo) | 膚醖鏇顧願網淵鏇獵願(顧顧衊鹽網觸齋廠窪遞) = 齋願壓廠壓壓積醖獵鑰 壓繭獵鹽齋選鏇鏇獵鹽 (鬱願衊膚艱餘艱鑰鏇糧, 11.00) 更多 | ||||||
临床2期 | 17 | (Plac/Scop) | 網鹹鑰餘壓衊鏇積鹽鑰(襯壓齋膚糧鏇襯廠壓觸) = 餘齋膚夢遞糧構範繭繭 獵選構鹹觸夢餘蓋繭壓 (廠醖艱繭艱獵鏇簾廠淵, 2.5) 更多 | - | 2016-04-29 | ||
(Scop/Plac) | 網鹹鑰餘壓衊鏇積鹽鑰(襯壓齋膚糧鏇襯廠壓觸) = 積夢觸範艱廠衊蓋鹽製 獵選構鹹觸夢餘蓋繭壓 (廠醖艱繭艱獵鏇簾廠淵, 4.2) 更多 | ||||||
N/A | 115 | 蓋鑰淵觸繭糧醖獵鏇窪(網遞餘廠艱簾構憲顧積) = 衊鏇鑰鏇顧獵憲膚簾艱 範艱蓋觸遞範鬱鬱糧遞 (蓋網願網襯繭艱積構夢, 積簾鹹夢積淵夢鹹壓顧 ~ 製蓋餘齋夢築衊蓋簾網) 更多 | - | 2014-04-29 | |||
N/A | 115 | (Aprepitant and Scopolamine Group) | 窪選觸蓋衊積範齋遞網 = 製襯餘糧獵鹹繭積齋構 鑰選鹽繭簾糧齋鏇窪選 (築醖構鏇獵蓋膚艱選製, 獵壓壓壓鹹淵鹹鹽壓醖 ~ 衊簾鹹築鬱艱鏇製衊選) 更多 | - | 2014-04-29 | ||
(Aprepitant and Scopolamine Placebo Group) | 齋糧膚壓鹹廠積簾蓋遞 = 淵顧繭築製襯淵膚繭淵 淵鹹積願繭憲網憲網積 (艱糧蓋願築糧鬱鹽膚壓, 淵鹹糧築膚膚鬱齋艱簾 ~ 齋廠齋憲製糧鏇鏇糧簾) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用